Meet Our Leadership Team
FRANK G. HOWARD
Founder & Chief Executive Officer
Frank earned his B.A. in Economics from Southern Methodist University and has led successful toxicology and molecular diagnostic testing laboratories for 8 years, serving vast amounts of clients throughout North America. He is also the founder and CEO of the Gulfstream Companies (Gulfstream Health and Gulfstream Capital). Gulfstream's focus is on opportunistic private debt and equity transactions, and its subsidiaries have deployed in excess of $400m of equity across 75+ investments throughout the United States. Gulfstream has a diverse asset base of passive and active investments focused in healthcare.
ANDRE L. JOHNSON
Chief Administrative Officer
Andre has more than 20 years of professional experience in human resources, including training and development for startup, nonprofit and publicly traded organizations. He oversees all human capital and administrative operations.
JOHN R. HARRIS
Board of Directors and Advisor
John has extensive experience in CEO and senior executive positions, leading technology-based service companies and creating shareholder value. He has served on private and public company boards as chairman and lead director and chaired audit and compensation committees.
National Director of Business Development
Bobby has more than 17 years of proven Sales and Operations experience in the laboratory industry. Prior to joining geneIQ, he was Vice President of Strategic Accounts at NeoDiagnostix, a leader in cervical cancer genomics. Aside from owning his own clinical lab for several years, prior to an acquisition by Quest Diagnostics, he has held several sales leadership positions in the clinical lab space.
Director of Long-Term Care
Stacy has been a leader in the Senior Care Industry for over 20 years.
As a licensed long-term care home administrator, she has supported and served thousands of residents, families and teams through their journey in Senior Care. She started in the business at age 23 and has built and grown many programs and organizational cultures along the way.
National Accounts Manager
Mark has worked in a variety of industries over his career and has spent the Iast 12 years in and around the healthcare industry. His healthcare assignments have included CPT/ICD coding accuracy improvement, medical record documentation completeness, and medical lien specialty finance. As an award-winning entrepreneur, Mark led one of his companies to be named Virginia's Business of the Year.
Meet Our Scientific Team
DR. TARIQ ADWAN PhD
Chief Scientific Officer
Dr. Adwan graduated with honors from Misericordia University with a B.S. in Biology and Chemistry. He received his Ph.D. in Cell Biology, Stem Cells and Development from the University of Colorado where he also did his postdoctoral fellowship. His research focused on understanding the molecular mechanism underlying salivary gland dysfunction in head and cancer patients. While a graduate student and postdoctoral fellow, Dr. Adwan received numerous grants and awards including the National Research Service Award from the National Institute of Health. In addition, Dr. Adwan is co-author of numerous high-impact, peer reviewed publications. He has been invited to present his work at various scientific meetings including the conference for the Federation of American Societies for Experimental Biology on Lipid Mediated Signaling in Cancer. Before joining our team, Dr. Adwan worked as an assistant professor at An-Najah National University, in their School of Medicine.
DR. TABETHA SUNDIN PhD, HCLD (ABB), MB (ASCP)CM
Dr. Sundin graduated from Old Dominion University where she completed her B.S. in Biology, Ph.D. in Biomedical Sciences, and Postdoctoral Fellowship. She has over 10 years of laboratory experience in cancer biology and clinical molecular diagnostics and is an active member of the Association of Molecular Pathology (AMP). She is widely published and speaks at various symposiums about multidisciplinary facilitation of biomarker testing in cancer patients on behalf of AstraZeneca and Bristol-Myers Squibb. She’s involved with numerous efforts to support the molecular diagnostics field in collaboration with American Medical Technologists (AMT) and the Clinical & Laboratory Standards Institute (CLSI).